Insider filing
Traded Jun 25 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jun 4, 2026 · Filed Jun 5, 2026
A Krystal Biotech director sold $147K of Krystal Biotech shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$146,815
Shares × reported transaction price
107 days after results of Feb 17, 2026, 60 days before results of Aug 3, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $307.79 on Jun 4, 2026, within 3% of its 52-week high, after a 12% rise over the previous 30 trading days
52-week range $130.02 (Jun 17, 2025) to $316.30 (May 14, 2026), 95% of the way up, from 251 adjusted closes. 30 trading days earlier: $275.94 on Apr 22, 2026. Describes the past only, not a forecast
RSI 58, 31% above its 200-day average, 9% above its 50-day average, 3% below the 52-week high, 20-day volatility 36% a year, against the S&P 500: +4 points over 1 month, +7 points over 3 months, +32 points over 6 months
From the adjusted closes up to Jun 4, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +7.6% | +2.1% | +5.5% |
| 30 days | +24.4% | +0.8% | +23.6% |
| 90 days | +16.4% | +3.6% | +12.8% |
Past results only. Not a forecast.
Insider filing
Traded Jun 25 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
John Charles Thomas (EVP, General Counsel) sold ~$347K of Krystal Biotech
Planned saleInsider filing
Traded Jun 25 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
The company's first weighty Form 8-K report after this date: reported its results, 60 days later (Aug 3, 2026).